pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
deramiocel · news · pharmadog
← back to deramiocel
News mentioning deramiocel
48
stories
19h
FDA again turns back Capricor Duchenne cell therapy
biopharma dive
1d
Capricor’s regulatory odyssey for DMD cell therapy hits second FDA rejection
biospace
1d
Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trial
endpoints
1d
STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
stat
11d
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
biospace
11d
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
biospace
11d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
11d
Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
fiercebiotech
11d
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
biospace
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
Oct 15, 26
FDA's latest rare disease framework seeks to prioritize consistency in flexibility
biospace
Sep 24, 26
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
Sep 21, 26
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
Sep 3, 26
Capricor, Replimune illustrate why FDA must listen to rare disease specialists
biospace
Aug 26, 26
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
biospace
Aug 25, 26
Capricor secures reprieve as FDA extends DMD cell therapy review
fiercebiotech
Aug 24, 26
FDA extends review of Capricor cell therapy; Pain drug startup to go public
biopharma dive
Aug 24, 26
Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
biospace
Aug 24, 26
FDA delays Capricor's deramiocel PDUFA date to review new data
endpoints
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 21, 26
Capricor investor calls for change as company awaits decision on Duchenne candidate
biospace
Aug 20, 26
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
Aug 20, 26
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Jul 31, 26
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
← prev
page 1 of 2
next →